Altos Labs

Partial epigenetic reprogramming · Multi-organ aging

PreclinicalPartial Epigenetic Reprogramming

Mechanism

Partial epigenetic reprogramming

Intervention class

Cell / epigenetic

Indication

Multi-organ aging

Stage

Preclinical

Evidence

animal

Funding

$3.0B founding

Backers

Bezos, Yuri Milner, ARCH

Overview

The most capitalized startup in history at launch. Pursuing in vivo partial reprogramming to reset cellular age without losing cell identity. No disclosed clinical asset yet — pure platform play on Yamanaka-factor biology.

Technology

Altos Labs works in Partial Epigenetic Reprogramming — Rewinding a cell's biological age without erasing what it is.

Read the Partial Epigenetic Reprogramming brief →

Related companies

Retro Biosciences

Reprogramming, autophagy, plasma factors

Life Biosciences

Partial reprogramming (OSK via AAV)

NewLimit

Epigenetic reprogramming (factor discovery)

Rejuvenate Bio

Gene therapy (FGF21, sTGFβR2, klotho); reprogramming

Turn Biotechnologies

mRNA epigenetic reprogramming

Shift Bioscience

Reprogramming w/o dedifferentiation

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.